USE OF BUBUC AND OPTIONAL EAA-MARTI (26-35) AS A THERAPEUTIC FOR THE TREATMENT OF HCMV INFECTIONS

摘要

1. The combination of the peptides Tyr-D-Cys (tBu) -Gly-Phe-Leu-Thr (tBu) -OH and Glu-Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val-OH or their salts or hydrates. ! 2. The combination according to claim 1, where the peptides are contained in combination in an amount of from 30 wt.% To 70 wt.% To 70 wt.% To 30 wt.%. ! 3. The combination according to claim 1 for use in medicine. !four. The use of the Tyr-D-Cys (tBu) -Gly-Phe-Leu-Thr (tBu) -OH peptide or a combination according to claim 1, 2, or 3 for the preparation of a pharmaceutical composition for the treatment and / or prevention of a malignant tumor, autoimmune diseases fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and blood vessel diseases and metabolic diseases. ! 5. The use of the peptide according to claim 4, where the malignant tumor, autoimmune disease, fibrosis, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and blood vessel disease or metabolic disease are selected from HBV infection, human cytomegalovirus infection, diseases associated with human cytomegalovirus infection, and also due to HCMV infection in patients with immune deficiency, in transplant organ recipients, in patients undergoing hemodialysis, in cancer patients, in patients receiving immunosuppressive drugs, and in HIV-infected patients, and in patients suffering from pneumonia, gastrointestinal disease, retinal disease, neurological disease, hearing loss, visual impairment, liver failure and colitis, indicated higher diseases in patients with immune deficiency, in transplant recipient recipients, in patients with